Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
69
days
How to Optimize Healthy Volunteer Screening and Enrolment in Clinical Trials: A Qualitative and Quantitative Approach to Evaluate Processes and Healthy Volunteers' Perceptions
AuthorsEvelyn Krohmer; Manuela König; Cathrin J. Vogt; Marina Streckebein; Sybille Baumann; Max Blumenstock; Ruwen Böhm; Fabian Müller; Nadja Struß; Viktoria S. Wurmbach; Antje Blank
Affiliations1. Internal Medicine IX, Department of Clinical Pharmacology and Pharmacoepidemiology Medical Faculty Heidelberg University/Heidelberg University Hospital Heidelberg Germany; 2. CRS hVIVO Mannheim Germany; 3. CRS Berlin Germany; 4. Institute of Medical Informatics Heidelberg University Heidelberg Germany; 5. Socratec Erfurt Germany; 6. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach an der Riß Germany; 7. Institute of Experimental and Clinical Pharmacology and Toxicology Friedrich‐Alexander‐Universität Erlangen‐Nürnberg Erlangen Germany
70
days
Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations
AuthorsXinyu Liu; Zhigang Liu; Xiaohu Kuang; Yueming Wang; Xiaoyi Liu; Jiyuan Ding; Xia Zhou; Xin Zhou; Qianyu Liang; Meizhuo Zhang; Hao Zhao; Qingqing Tan; Weihong Zheng; Huaxin Liao; Charlotte Lemech; Wanmei Wang
Affiliations1. Zhuhai Trinomab Pharmaceutical Co., Ltd. Zhuhai China; 2. The Fifth Affiliated Hospital Sun Yat‐sen University Zhuhai China; 3. Present address: Cancer Center, The Tenth Affiliated Hospital Southern Medical University (Dongguan People's Hospital) Dongguan China; 4. Scientia Clinical Research Ltd. Sydney Australia
195
days
Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer
AuthorsVaishali L. Chudasama; Helen Kastrissios; Hossam Kadry; Daping Zhang; Salaheldin Hamed; Srinivasu Poondru; Souvik Bhattacharya; Russ Wada; Amit Garg; Yen Lin Chia
Affiliations1. Pfizer Inc New York New York USA; 2. QuanTx Consulting Mountain View California USA; 3. Astellas Pharma Northbrook Illinois USA; 4. BeOne Medicines San Carlos California USA
103
days
Effects of Fomepizole on Acetaminophen Oxidative Metabolism: A Randomized, Crossover Study in Human Volunteers
AuthorsSidharth Anand; Nicholas A. Buckley; Paul Stathakis; Laura James; Larry Parker; Mitchell R. McGill; Angela L Chiew
Affiliations1. Faculty of Medicine The University of New South Wales Sydney New South Wales Australia; 2. Faculty of Medicine and Health The University of Sydney Camperdown New South Wales Australia; 3. NSW Health Pathology, Prince of Wales Hospital Randwick New South Wales Australia; 4. Department of Pediatrics, College of Medicine University of Arkansas for Medical Sciences Little Rock Arkansas USA; 5. Acetaminophen Toxicity Diagnostics, LLC Little Rock Arkansas USA; 6. Department of Environmental Health Sciences, Fay W. Boozman College of Public Health University of Arkansas for Medical Sciences Little Rock Arkansas USA; 7. Department of Pharmacology and Toxicology, College of Medicine University of Arkansas for Medical Sciences Little Rock Arkansas USA; 8. Department of Clinical Toxicology Prince of Wales Hospital Randwick New South Wales Australia
117
days
Epcoritamab Step‐Up Dosing Regimen Selection and Optimization Using Repeated Time‐to‐Event Modeling for Cytokine Release Syndrome Risk Mitigation
AuthorsTommy Li; Andrew Tredennick; Daniel Polhamus; Matthew Putnins; Sihang Liu; Kinjal Sanghavi; Craig J. Thalhauser; Apurvasena Parikh; Behnam Noorani; Mohamed‐Eslam F. Mohamed; Chris Le Gallo; Brian Elliott; Manish Gupta; Steven Xu
Affiliations1. Genmab Princeton New Jersey USA; 2. Metrum Research Group Boston Massachusetts USA; 3. AbbVie Inc. North Chicago Illinois USA
125
days
From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI
AuthorsMichael McCoy; Matthew McCoy
Affiliations1. Drug Metabolism and Pharmacokinetics & Modeling, Takeda Development Center Americas Cambridge Massachusetts USA; 2. Independent Researcher Kansas City Missouri USA
9
days
The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient
AuthorsRichard W. Peck
Affiliations1. Department of Pharmacology & Toxicology University of Liverpool Liverpool UK
81
days
Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi‐Regional Clinical Trials and Future Pathways
AuthorsYosuke Kobayashi; Nobuko Matsushima; Noriyuki Takai; Daisuke Sato; Shinichiro Hoshino; Akihiro Ishiguro; Yasuo Iimura
Affiliations1. Pharmaceuticals and Medical Devices Agency Tokyo Japan; 2. Johnson & Johnson J&J Innovative Medicine Tokyo Japan; 3. Drug Evaluation Committee Japan Pharmaceutical Manufacturers Association Tokyo Japan; 4. EPS Corporation Tokyo Japan; 5. Ministry of Health, Labour and Welfare Tokyo Japan; 6. Eli Lilly Japan K.K. Kobe Japan
100
days
Resolving CYP2D6 Structural Complexity with Long‐Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients
AuthorsUsa Boonyuen; Sirinyatorn Talukam; Beatriz Aira C. Jacob; Wayu Matphong; Kamonwan Chamchoy; Onrapak Reamtong; Nuntana Meesiripan; Junya Yamagishi; Matthew Phanchana; Chayanoot Rattadilok
Affiliations1. Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine Mahidol University Bangkok Thailand; 2. Princess Srisavangavadhana Faculty of Medicine Chulabhorn Royal Academy Bangkok Thailand; 3. National Cancer Institute Bangkok Thailand; 4. International Institute for Zoonosis Control Hokkaido University Hokkaido Japan
123
days
Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin–Angiotensin System Inhibitors
AuthorsKatherine L. Crum; Muthiah Vaduganathan; Rishi J. Desai
Affiliations1. Department of Epidemiology Harvard T.H. Chan School of Public Health Boston Massachusetts USA; 2. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA; 3. Division of Cardiovascular Medicine Brigham and Women's Hospital Boston Massachusetts USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days